Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01097018 · ClinicalTrials.gov registry record · Phase 3
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase 3 study, sponsored by AEterna Zentaris.
- Completed
- Registry status
- Phase 3
- Development phase
- 468
- Enrollment target
NCT01097018 is a Phase 3 study that has completed, run by AEterna Zentaris. The registered enrollment target is 468 participants.
The verdict
NCT01097018, a Phase 3 study, has completed, sponsored by AEterna Zentaris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 468 participants
- Enrollment target
Study Summary
The trial will compare the overall survival of perifosine plus capecitabine to placebo plus capecitabine in patients with refractory advanced colorectal cancer.
Interventions
- DRUG Placebo
- DRUG Capecitabine
- DRUG Perifosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 468 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01097018
The ClinicalTrials.gov registry entry for NCT01097018 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 468 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AEterna Zentaris, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01097018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01097018 about?
NCT01097018 is a clinical study titled "Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer". The trial will compare the overall survival of perifosine plus capecitabine to placebo plus capecitabine in patients with refractory advanced colorectal cancer.
What is the current status of trial NCT01097018?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 468 participants. The study started on 2010-04. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01097018?
The interventions under investigation include: Placebo (DRUG), Capecitabine (DRUG), Perifosine (DRUG).
Who is sponsoring clinical trial NCT01097018?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.